Drug floats catch a cold

Article Abstract:

Antisoma plans a stock market flotation but this could be delayed until year-end 1997. United Kingdom investors have become less enthusiastic about biotechnology stocks following an announcement in May 1997 that Celltech's septic shock drug was not effective. Antisoma has an ovarian cancer treatment, Theragyn, in Phase 3 trials and this means investing in Antisoma is less of a risk. The company is likely to wait for market conditions to improve prior to announcing its flotation.

Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Anticancer Drugs, Antineoplastic agents, Antisoma PLC

---

Xenova: risky business

Article Abstract:

Xenova is a biotechnology company which produces drugs from plants and is seeking to raise 25 million pounds sterling through a placing. The company has three products at a late development phase, but they are not likely to be launched prior to 2001. The company needs funds before then, hence tthe share placing, and could need further funds thereafter. The company has made agreements with Warner Lambert and Suntory's pharmaceutical division to develop drugs.

Xenova Group PLC

---

PPL Therapeutics: flocking to market

Article Abstract:

PPL Therapeutics is a UK biotechnology company planning a listing in Jun 1996. The company can alter sheep genetically to produce proteins in sheep's milk which is of use to drugs companies. The company reported a loss of 1.4 million pounds sterling for 1995, with revenue at 4.5 million pounds. The share flotation is likely to raise from 25 million pounds sterling to 30 million pounds, to be investment in developing new products.

PPL Therapeutics PLC

Similar abstracts:

• Abstracts: Students and concepts. Serious fun: the business of toys. Running with scissors
• Abstracts: Toy story hurts Argos. Retailers catch a cold. Paying through the nose
• Abstracts: Profit margins to take a pounding. Sterling labours under an illusion. Sterling: a pounding
• Abstracts: Deal flow continues to delight. A user's guide. Factoring and invoice discounting: respectable image leads to growth
• Abstracts: Astec (BSR). AF Bulgin: green shoots. Telemetrix

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.